TTrialPathMatch Me to Trials
← Back to trials
RecruitingDiabetes Mellitus, Type 2PreDiabetesMetabolic Syndrome

A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events

Eligible age

55+ yrs

Accepts

All genders

Locations

33 states

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (CAD) Staging System-based care strategy reduces CV events compared with risk factor-based care.

Sponsor: Cleerly, Inc.

You may qualify if…

  • ✓ 1. Provided electronic or written informed consent
  • ✓ 2. Men \> 55, women \> 65 years of age
  • ✓ 3. Type 2 diabetes mellitus requiring pharmacologic therapy or with their most recent A1c 6.5%. Patients with prediabetes (most recent HbA1c 5.7 to 6.4% and/or fasting glucose 100-125 mg/dL \[5.6-6.9 mmol/L\]) and/or metabolic syndrome can be enrolled through 12 October 2026 and proceed with randomization; however, no additional participants may enroll with these criteria after this date. Metabolic syndrome is defined as \> 3 of the following criteria (International Diabetes Federation 2006):
  • ✓ Body mass index ≥ 27 kg/m2 or abnormal waist circumference defined as ≥ 80 cm (31.5 inches) for women, ≥ 94 cm (37 inches) for men; for South and East Asian men (e.g., Asian Indian, Chinese, Japanese) ≥ 90 cm (35.4 inches)
  • ✓ Fasting triglycerides ≥ 150 mg/dL (1.7 mmol/L) or treated hypertriglyceridemia
  • ✓ HDL-cholesterol (HDL-C) \< 40 mg/dL (1.03 mmol/L) in men, \<50 mg/dL (1.29 mmol/L) in women or treatment for this lipid abnormality
  • ✓ Systolic blood pressure (BP) ≥ 130 and/or diastolic BP≥ 85 mm Hg and/or treated hypertension
  • ✓ Fasting blood glucose ≥ 100 mg/dL (5.6 mmol/L) or HbA1c ≥ 5.7%

You may not qualify if…

  • ✕ 1. Any one of the following:
  • ✕ 1. A history of acute myocardial infarction (heart attack), stroke, or non-traumatic leg/foot/toe amputation
  • ✕ 2. A history of an arterial revascularization procedure for coronary, peripheral, and/or carotid atherosclerotic disease (i.e. coronary stent or bypass, carotid stent)
  • ✕ 3. Symptoms suspicious of coronary artery disease, stroke or peripheral artery disease confirmed by a diagnostic test within the last 12 months (i.e. nuclear stress test, invasive angiogram, brain MRI/CT
  • ✕ 4. Asymptomatic ASCVD including treatment with therapies (e.g. antiplatelets, lipid lowering) intended to reduce CV risk due to the imaging evidence of atherosclerosis and/or management to goals consistent with secondary prevention guidelines (e.g. LDL-C \< 70 mg/dL)
  • ✕ 2. Planned arterial revascularization
  • ✕ 3. Inability to complete screening CCTA or any condition that would increase the risk associated with CCTA or increase likelihood of uninterpretable scan including:
  • ✕ 1. eGFR \< 60 mL/min/1.73 m2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) or Modification of Diet in Renal Disease (MDRD) equation (www.kidney.org/professionals/kdoqi/gfr\_calculator)

Where it's recruiting

Arizona

Chandler · Scottsdale · Sun City · Tucson

California

Beverly Hills · Canoga Park · Chula Vista · Granada Hills …

Colorado

Aurora · Denver

Florida

Boca Raton · Cross City · Hialeah · Jacksonville …

Georgia

Augusta · Dunwoody · Fayetteville · Lithia Springs …

Idaho

Meridian

Illinois

Chicago · Glenview

Indiana

Indianapolis

Iowa

West Des Moines

Kentucky

Edgewood · Louisville

Louisiana

New Orleans

Maryland

Bowie · Columbia

Source: ClinicalTrials.gov · NCT06112418 · last updated 2026-11-19